FDA to Review NDA for Faster-Acting Insulin Aspart

FDA to Review NDA for Faster-Acting Insulin Aspart
FDA to Review NDA for Faster-Acting Insulin Aspart

Novo Nordisk announced the submission to the Food and Drug Administration (FDA) of a New Drug Application (NDA) for faster-acting insulin aspart for the treatment of type 1 and type 2 diabetes.

The NDA submission is based on results from the clinical trial program that evaluated the safety and efficacy of mealtime and after-meal faster-acting insulin aspart in approximately 2,100 adults with type 1 and type 2 diabetes.

RELATED: Diabetes Treatments Chart

Faster-acting insulin aspart is an investigational mealtime insulin which contains a short-acting insulin with a vitamin and an amino acid excipient for faster initial absorption rate and earlier glucose lowering effect.

Novo Nordisk intends to develop the faster-acting insulin aspart in a pre-filled delivery device FlexTouch and a 10mL vial upon approval.

For more information call (800) 727-6500 or visit Novonordisk-us.com.

Loading links....